Enzyme Replacement Therapy
"Enzyme Replacement Therapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Therapeutic replacement or supplementation of defective or missing enzymes to alleviate the effects of enzyme deficiency (e.g., GLUCOSYLCERAMIDASE replacement for GAUCHER DISEASE).
| Descriptor ID |
D056947
|
| MeSH Number(s) |
E02.319.353.500
|
| Concept/Terms |
Enzyme Replacement Therapy- Enzyme Replacement Therapy
- Enzyme Replacement Therapies
- Replacement Therapies, Enzyme
- Replacement Therapy, Enzyme
- Therapies, Enzyme Replacement
- Therapy, Enzyme Replacement
|
Below are MeSH descriptors whose meaning is more general than "Enzyme Replacement Therapy".
Below are MeSH descriptors whose meaning is more specific than "Enzyme Replacement Therapy".
This graph shows the total number of publications written about "Enzyme Replacement Therapy" by people in this website by year, and whether "Enzyme Replacement Therapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 0 | 2 | 2 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 2 | 2 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 1 | 2 |
| 2021 | 0 | 2 | 2 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Enzyme Replacement Therapy" by people in Profiles.
-
Ream MA, Lam WKK, Grosse SD, Ojodu J, Jones E, Prosser LA, Ros? AM, Comeau AM, Tanksley S, Powell CM, Kemper AR. Evidence and recommendation for mucopolysaccharidosis type II newborn screening in the United States. Genet Med. 2023 02; 25(2):100330.
-
Ginns EI, Ryan E, Sidransky E. Gaucher disease in the COVID-19 pandemic environment: The good, the bad and the unknown. Mol Genet Metab. 2021 04; 132(4):213-214.
-
McCall AL, Dhindsa JS, Bailey AM, Pucci LA, Strickland LM, ElMallah MK. Glycogen accumulation in smooth muscle of a Pompe disease mouse model. J Smooth Muscle Res. 2021; 57(0):8-18.
-
Khan AA, Case LE, Herbert M, DeArmey S, Jones H, Crisp K, Zimmerman K, ElMallah MK, Young SP, Kishnani PS. Higher dosing of alglucosidase alfa improves outcomes in children with Pompe disease: a clinical study and review of the literature. Genet Med. 2020 05; 22(5):898-907.
-
ElMallah MK, Desai AK, Nading EB, DeArmey S, Kravitz RM, Kishnani PS. Pulmonary outcome measures in long-term survivors of infantile Pompe disease on enzyme replacement therapy: A case series. Pediatr Pulmonol. 2020 03; 55(3):674-681.
-
Lewis G, Morrill AM, Conway-Allen SL, Kim B. Review of Cerliponase Alfa: Recombinant Human Enzyme Replacement Therapy for Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2. J Child Neurol. 2020 04; 35(5):348-353.
-
Min M, Patel B, Han S, Bocelli L, Kheder J, Vaze A, Wassef W. Exocrine Pancreatic Insufficiency and Malnutrition in Chronic Pancreatitis: Identification, Treatment, and Consequences. Pancreas. 2018 09; 47(8):1015-1018.
-
Han S, Patel B, Min M, Bocelli L, Kheder J, Wachholtz A, Wassef W. Quality of life comparison between smokers and non-smokers with chronic pancreatitis. Pancreatology. 2018 Apr; 18(3):269-274.
-
Maron MS, Xin W, Sims KB, Butler R, Haas TS, Rowin EJ, Desnick RJ, Maron BJ. Identification of Fabry Disease in a Tertiary Referral Cohort of Patients with Hypertrophic Cardiomyopathy. Am J Med. 2018 02; 131(2):200.e1-200.e8.
-
Rost NS, Cloonan L, Kanakis AS, Fitzpatrick KM, Azzariti DR, Clarke V, Lourenco CM, Germain DP, Politei JM, Homola GA, Sommer C, ??eyler N, Sims KB. Determinants of white matter hyperintensity burden in patients with Fabry disease. Neurology. 2016 May 17; 86(20):1880-6.